Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Anticancer activity of an Artemisia annua L. hydroalcoholic extract on canine osteosarcoma cell lines

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Salaroli, R., Andreani, G., Bernardini, C., Zannoni, A., La Mantia, D., Protti, M., et al. (2022). Anticancer activity of an Artemisia annua L. hydroalcoholic extract on canine osteosarcoma cell lines. RESEARCH IN VETERINARY SCIENCE, 152, 476-484 [10.1016/j.rvsc.2022.09.012].

Availability:

This version is available at: https://hdl.handle.net/11585/899294 since: 2022-11-03

Published:

DOI: http://doi.org/10.1016/j.rvsc.2022.09.012

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version.

(Article begins on next page)

1 Anticancer activity of an Artemisia annua

2 L. hydroalcoholic extract on canine

3 osteosarcoma cell lines

- 4 Roberta Salaroli¹, Giulia Andreani^{1*}, Chiara Bernardini¹,
- 5 Augusta Zannoni¹, Debora La Mantia¹, Michele Protti², Monica
- 6 Forni¹, Laura Mercolini², Gloria Isani¹
- ¹Department of Veterinary Medical Sciences (DIMEVET), Alma
- 8 Mater Studiorum University of Bologna, 40064 Ozzano Emilia,
- 9 Bologna, Italy.
- 10 ² Pharmaco-Toxicological Analysis Laboratory (PTA Lab),
- 11 Department of Pharmacy and Biotechnology (FaBiT), Alma
- 12 Mater Studiorum University of Bologna, 40126 Bologna, Italy*
- 13 Corresponding author* at: via Tolara di Sopra 50, 40064
- 14 Ozzano Emilia, Bologna, Italy.
- 15 E-mail addresses:
- 16 roberta.salaroli@unibo.it (R. Salaroli)
- 17 *giulia.andreani2@unibo.it (G. Andreani)
- 18 chiara.bernardini5@unibo.it (C. Bernardini)
- 19 debora.lamantia2@unibo.it (D. La Mantia)
- 20 michele.protti2@unibo.it (M. Protti)
- 21 monica.forni@unibo.it (M. Forni)
- 22 laura.mercolini@unibo.it (L. Mercolini)
- gloria.isani@unibo.it (G. Isani)

24 Abstract

25 Since ancient times, Artemisia annua (A. annua) has 26 been used as a medicinal plant in Traditional Chinese 27 Medicine. In addition. recent studies 28 investigated the cytotoxic effects of *A. annua* extracts 29 towards cancer cells. The leading aim of the present 30 research is to evaluate the cytotoxic effects of an 31 hydro alcoholic extract of A. annua on two canine 32 osteosarcoma (OSA) cell lines, OSCA-8 and OSCA-33 40, focusing on the possible involvement of 34 ferroptosis. 35 The quantitative determination of Artemisinin 36 concentration in the extract, culture medium and 37 OSA cells was carried out through the use of an 38 instrumental analytical method based on liquid 39 chromatography coupled with spectrophotometric 40 detection and tandem mass spectrometry (HPLC-41 DAD-MS/MS). OSCA-8 and OSCA-40 were exposed 42 to different dilutions of the extract for the EC₅₀ 43 calculation then the uptake of Artemisinin by the cells, 44 the effects on the cell cycle, the intracellular iron 45 level, the cellular morphology and the lipid oxidation state were evaluated. A concentration of Artemisinin 46 47 of 63.8 \pm 3.4 μ g/mL was detected in the extract. A 48 dose-dependent cytotoxic effect was evidenced. In

OSCA-40 alterations of the cell cycle and a significantly higher intracellular iron content were observed. In both cell lines the treatment with the extract was associated with lipid peroxidation and with the appearance of a "ballooning" phenotype suggesting the activation of ferroptosis. In conclusion the *A. annua* idroalcoholic extract utilized in this study showed anticancer activity on canine OSA cell lines that could be useful in treating drug resistant canine OSAs.

Keywords: Artemisia annua, canine osteosarcoma
 cell lines, iron, lipid peroxidation, balloning
 phenotype, ferroptosis.

63 1. Introduction

Extracts of *Artemisia annua* L. are well-known remedies in Chinese Traditional Medicine and have been used to treat malaria and fever in Asia and Africa [1]. *A. annua* is characterized by the unique presence of artemisinin, a sesquiterpene trioxane lactone, which contains an endoperoxide bridge essential for its bioactivity. Artemisinin and its derivatives demonstrated also anticancer activity in

different human and animal cancer cell lines [2], targeting different pathways, including inhibition of proliferation, induction of apoptosis, inhibition of angiogenesis and metastasis [3]. In addition, artemisinin reveals an additional anticancer mechanism through induction of ferroptotic cell death [4]. To sustain increased proliferation, tumour cells have high iron requirement, a phenomenon also known as "iron addiction" and are characterized by high intracellular iron content [5]. The endoperoxide artemisinin bridge of is strategic for its pharmacological activity, in fact its cleavage leads to the formation of radical species and induces oxidative stress [6]. In addition, in the presence of reduced ferrous ions or heme iron, artemisinin can become a potent alkylating agent, capable of inducing direct oxidative damage. Consequently, an lipid iron-mediated lethal peroxidation called ferroptosis can occurs in cancer cells leading to cell death [7, 8]. Thus, iron plays an important role in the selective toxicity of artemisinin towards cancer cells. Osteosarcoma (OSA) is the most common primary bone tumour in dogs and humans [9-11]. In veterinary medicine, OSA accounts for 2-5% of all canine neoplasms [7] and 80-85% of all bone tumours [12].

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

with Α study on 162 dogs appendicular osteosarcoma reported a median survival of 19.2 weeks. The one-year and two-year survival rates are 11.5% and 2%, respectively. Many dogs die or are suppressed due to the presence of pulmonary metastases [13]. Current treatment for canine OSA (cOSA) involves surgery to remove primary tumours; however, dogs treated with surgery alone have a short survival time. Surgery combined chemotherapy can increase the survival of dogs with OSA, and protocols include doxorubicin, cisplatin, and carboplatin used alone or in combination [12]. However, drug resistance is a critical issue determining the failure of therapy in many cases. Therefore, it would be of paramount importance implement the choice of possible drugs to be used in chemotherapy and also to provide low-cost treatment for those animals that do not have access to chemotherapy for economic reasons. Two previous in vitro studies have demonstrated the cytotoxicity of dihydroartemisinin on different cOSA cell lines [14] and of an hydroalcoholic extract and pure artemisinin on cOSA D-17 cell line [15, 16]. The aim of this research is to deepen the knowledge on the cytotoxic and anti-proliferative effects of an

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

hydroalcoholic commercial extract of *A. annua* on two additional canine osteosarcoma cell lines, OSCA-8 and OSCA-40, focusing on the possible involvement of ferroptosis. In detail, to provide more specific therapeutical indications, the aims of the work were to determine: i) the concentration of Artemisinin in the phytoextract and in the culture media and cells after the treatment; ii) the cytotoxicity and the antiproliferative effects of the extract; iii) the intracellular iron content alteration following the treatment. All tests have been performed for comparison also with the primary compound Artemisinin.

2. Materials and Methods

Cells, chemicals and reagents

Canine osteosarcoma cell lines OSCA-8 and OSCA-40 were purchased from Kerafast, Inc. (Boston, MA, USA). Minimum Essential Medium (MEM) with GlutaMAX, Foetal Bovine Serum (FBS), Antibiotic-Antimycotic solution, Dulbecco Phosphate Buffered Saline (DPBS), DPBS without calcium and magnesium (PBS w/o Ca²⁺ and Mg²⁺), RNaseA/T1 were purchased from Thermo Fisher Scientific

(Waltham, MA, USA). Dimethyl Sulfoxide (DMSO), FluoroshieldTM histology mounting medium and erastin were purchased from Merck (Darmstadt, Germany). Propidium iodide (PI) and Hoechst 33342 staining solution were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Lipid Peroxidation Assay Kit was purchased from Abcam (Cambridge, UK). All plastic supports for cell culture and 8-well slide chambers were purchased from Corning-Beckton-Dickinson (Franklin Lakes, NJ, USA). Artemisinin (CAS number: 63968-64-9), acetonitrile, methanol, formic acid (all mass spectrometry-grade) were obtained from Sigma Aldrich (St. Louis, MO, USA). Artemisinin-D3 pure powder, used as the internal standard (IS), was provided by Biosynth (St. Gallen, Switzerland). All solutions used for LC-DAD-MS/MS analysis were stored protected from light in amber glass vials certified for mass spectrometry from Waters Corporation (Milford, MA, USA). A commercial hydroalcoholic extract obtained from aerial parts of A. annua and composed by 65% ethanol, 20% of aerial parts and water was used (Artemisia annua hydroalcoholic solution, Sarandrea Marco C. srl, Fr, Italy).

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

MEPS-LC-DAD-MS/MS determination

of

170 artemisinin

169

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Quali-quantitative analytical determinations were carried out exploiting a previously developed and fully validated methodology based on microextraction by packed sorbent (MEPS) coupled to liquid chromatography with diode array detection and tandem mass spectrometry (LC-DAD-MS/MS) for the determination of Artemisinin in extracts commercial products [17]. Briefly, LC-DAD-MS/MS analysis was performed using a Waters (Milford, MA, USA) Alliance e2695 chromatographic system equipped with autosampler coupled to a Waters 2998 photodiode array detector and a Waters Micromass Quattro Micro triple-quadrupole mass spectrometer, interfaced with an electrospray ion source working in positive ionisation mode (ESI+). Chromatography was obtained a Restek (Bellefonte, PA, US) Ultra AQ reverse-phase C18 column (50 × 2.1mm I.D., 3µm), kept at room temperature and equipped with a C18 guard column (10 × 2.1mm I.D., 3µm), while injection volume was 10 µL. An automated composition gradient program managed a 2-component mobile phase composed of 0.25% formic acid in water (component A) and 0.25% formic acid in acetonitrile

194 (component B), flowing at a constant rate of 0.2 195 mL/min: T=0 min, A:B 70:30; T=2 min, A:B 10:90; 196 T=5 min, A:B 10:90; T=6 min, A:B 70:30; T=8, A:B 197 70:30. To detect Artemisinin, DAD was set at 232 nm, 198 while for MS/MS analysis, multiple reaction 199 monitoring (MRM) was used exploiting two different 200 exclusive m/z transitions (one for quantitative 201 purposes, one for qualitative confirmation) for both Artemisinin (283.24 \rightarrow 209.45; 283.24 \rightarrow 265.36) 202 203 and Artemisinin-D3, used as internal standard (IS, 204 $286.31 \rightarrow 212.38$; $286.31 \rightarrow 268.34$). For sample 205 pretreatment, all the samples involved in this study 206 (hydroalcoholic extract, cell pellets and cell culture 207 supernatant) were subjected to MEPS pretreatment 208 before LC analysis. Cell pellets from 1x10⁶ cells were 209 preliminarily homogenized in 0.1 M, pH 5.5 sodium 210 phosphate buffer (1 mL/sample). The mixtures were 211 centrifuged at 4000 rpm for 10 min (4 °C) and the 212 supernatants were collected. 100-µL aliquots of the 213 hydroalcoholic extract/cell pellet extract/cell culture 214 supernatant were then subjected to a MEPS 215 following a protocol developed ad-hoc for Artemisinin 216 analysis and involving a miniaturised apparatus 217 based on C8 sorbent [17].

Cell culture and treatments

OSCA-8 and OSCA-40 were cultured in MEM with GlutaMAX, 5% foetal bovine serum (FBS) and 1% antibiotic/antimycotic solution and expanded in T-25 or T-75 culture flasks at 2.5 x 10⁴ cells/cm² seeding density, at 37°C and 5% CO₂. The commercial extract was directly diluted in the culture medium to obtain the required artemisinin concentrations, based on the artemisinin concentration determined in the phytoextract as previously described. Artemisinin powder was firstly dissolved in DMSO and then diluited in the culture medium. Control cells were treated with equivalent amount of ethanol (ranging dilution 0.3-10%) or DMSO (0.05-3%) used as specific vehicles.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Cytotoxicity and EC₅₀ determination

The two cell lines were seeded in 96-well plates (1x10⁴ cells/well) and exposed, for 24 h, to increasing doses of Α. annua hydroalcoholic extract corresponding to Artemisinin concentrations of 0, 0.22, 0.44, 1.1, 2.2, 4.4, and 35.2 µM, calculated on the measured concentration of Artemisinin in the hydroalcoholic with extract or increasing concentrations of pure Artemisinin (0, 50, 100, 500, 1000, 2000, 3000 µM). Cytotoxicity was measured using tetrazolium salt (In Vitro Toxicology Assay Kit, MTT-based). Briefly, the MTT substrate was added to the culture medium and incubated for 3 h, then the MTT solubilization solution was added to the cells to dissolve the formazan crystals. The formazan absorbance was measured at a wavelength of 570 using Infinite[®] F50/Robotic Absorbance nm, microplate readers (TECAN, LifeScience). The background absorbance of multiwell plates at 690 nm was also measured and subtracted from the 570 nm measurements. EC50 values were calculated from dose-response curves using nonlinear regression analysis tool in GraphPad Prism 7 software [log(agonist) vs. normalized response - Variable slope] (GraphPad San Diego, CA, USA). Each assay was performed thrice independently, with seven replicates each.

Cell cycle analysis

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

OSCA-8 and OSCA-40 cells were seeded (2.5x10⁵) in 6-wells plates in complete medium and, when confluence reached round about 70%, cells were treated with *A. annua* hydroalcoholic extract and with Artemisinin EC₅₀ doses for 24 h in a humidified CO₂ incubator. EtOH and DMSO exposed cells were

267 considered as controls as described above. After 24 268 h of treatment, cells were harvested, counted, washed twice in 5 mL of DPBS w/o Ca²⁺ and Mg²⁺ 269 270 then fixed overnight in 70% ice-cold **EtOH** 271 $(1mL/1x10^6)$ cells) added drop-by-drop under 272 continuous vortex mixing. After fixation, the cells were washed with 10 mL DPBS w/o Ca²⁺ and Mg²⁺ 273 274 and cellular pellet was incubated with 1mL/10⁶ cells 275 of staining solution [50 μg/mL PI + 100 μg/mL RNaseA/T1 in DPBS w/o Ca²⁺ and Mg²⁺] for 30 min 276 277 in the dark at room temperature (RT). The DNA 278 contents 2N (G0/G1 phase), 2- 4N (S phase), and 279 4N (G2/M phase) were evaluated by MACSQuant® 280 Analyzer10 (Miltenyi Biotec, Bergisch Gladbach, 281 Germany) and Flow Logic software (Inivai 282 Technologies, Australia) as previously described 283 [18]. Dean-Jett-Fox Univariate Model was used to 284 determine the percentage of the cell population in the 285 distinct phases of the cell cycle [19]. The experiment 286 was repeated three times.

Iron quantification in OSCA-8 and OSCA-40

287

288

289

290

For the quantification of intracellular iron, cells were seeded and grown in wells as previously described.

Then, cells were treated with *A. annua* hydroalcoholic

extract or Artemisinin at the respective EC₅₀ doses, for 24 h. After the treatment cells were harvested and centrifuged at 800 x g for 10 min. The pellet was washed twice with DPBS, and then 1x10⁶ cells were resuspended in 1 ml of a solution of 1 M HNO₃, digested at room temperature until completely dissolved, and finally used for iron quantification Spectra AA-20 atomic using а absorption spectrometer (Varian) equipped with a GTA-96 graphite tube atomizer and a sample dispenser. Final data were expressed as pg Fe/cell. The optimization of the analytical method was obtained following Tüzen [20] with minor changes. The graphite tubes employed were coated GTA tubes (Agilent Technologies, Germany), the hollow cathode lamp current was 7 mA and measurements were performed at 248.3 nm resonance lines using a slit width of 0.2 spectral nm. During spectrophotometer readings, internal argon flow rate in the partition graphite tubes was maintained at 300 mL/min and was interrupted in the atomization phase. Ramp and hold times for drying, pyrolysis, atomization and cleaning temperatures optimized to obtain maximum absorbance without

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

315 significant background absorption, therefore, 316 background correction was not necessary. 317 The calibration curve was obtained by diluting 1 318 mg/mL standard stock solution of iron (Iron Standard 319 for AAS, Sigma-Aldrich, St Louis, Missouri, USA) with 320 Suprapur water (Supelco, St Louis, Missouri, USA) to 321 obtain working standards containing 0, 20, 40 and 60 322 ng/mL of iron and by plotting the absorbance at 248.3 323 nm against iron concentrations. The equation of the 324 curve was y = 0.0121x and the calculated regression 325 coefficient (r) was 0.996. The method was validated 326 with standard reference material (ERM® - BB422) 327 and the accuracy of the method, calculated as the 328 percentage of the certified value, resulted of 106 %. 329 limit (LOD), detection defined 330 concentration corresponding to 3 times the standard 331 deviation of 6 blanks, was 0.8 ng/mL

Light microscopic evaluation

332

333

334

335

336

337

338

OSCA-8 and OSCA-40 cell lines were treated for 24 h with *A. annua* hydroalcoholic extract, Artemisinin at the EC₅₀ dose or with erastin (10 μM) that triggers ferroptosis [21], an iron-dependent form of non-apoptotic cell death. The cell death morphology was observed and acquired using an inverted microscope

(Eclipse TS100, Nikon, Tokyo, Japan) equipped with
a digital camera (Digital C-Mount Camera TP3100,
Kowa, Aichi, Japan).

Lipid Peroxidation Assay

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Lipid peroxidation in OSCA-8 and OSCA-40 treated with A. annua hydroalcoholic extract or with Artemisinin was evaluated by the Lipid Peroxidation Assay Kit (Abcam, Cambridge, UK) following manufacturer's instructions. The day before the experiment 1x10⁵ cells/well were seeded in 8 well chamber slides and the cells were incubated for 24 h with A. annua hydroalcoholic extract, with Artemisinin at the respective EC₅₀ doses or with vehicle controls. To have positive controls OSCA-8 and OSCA-40 were treated with erastin (10 µM) for 24 h. Lipid Peroxidation Assay Kit uses a sensitive sensor that changes its fluorescence from red to green upon peroxidation by ROS in cells. The cells were also stained with Hoechst 33342 during the last 10 minutes of incubation with lipid peroxidation sensor. Fluorescence of the cells was monitored with a fluorescence microscope (Eclipse E600, Nikon) equipped with a digital camera (RETIGA-2000RV, Surrey, Canada) through FITC/TRITC channels.

Statistical analysis

363

370

371

Data for MTT were analysed with one-way analysis of variance (ANOVA) followed by post hoc Dunnett's multiple comparison test. Data of the cell cycle and iron content were analysed by paired Student's t-test. p < 0.05 was considered significant.

369 3. Results and discussion

Quantification of artemisinin in A. annua extract

and artemisinin cOSA uptake

372 For this purpose, a very sensitive method was 373 developed, based on high performance liquid 374 chromatography coupled to diode array detection 375 and tandem mass spectrometry (HPLC-DAD-376 MS/MS). This method was previously validated with 377 satisfactory results in terms of sensitivity (LOQ=5) ng/mL and LOD=1.5 ng/mL), linearity ($r^2 > 0.9995$ 378 379 over the 5-1000 ng/mL artemisinin concentration 380 extraction yield (>85 %), range), precision 381 (RSD%<3.5) and accuracy (88-93% range), allowing 382 determination an accurate of artemisinin concentrations in different matrices. 383 384 In the hydroalcoholic extract of A. annua considered 385 in this study, a concentration of artemisinin of 63.8 ± 386 3.4 µg/mL, corresponding to 0.23 mM, was detected. 387 The value is in accordance with those reported by 388 Protti et al. (2019) [17]. In that research, extracts 389 prepared ad hoc from herbal material by the authors 390 were analysed (Artemisinin concentration was 21.40 391 µg/mL for the hydroalcoholic extract and 109.40 392 µg/mL for the artemisinin-enriched extract prepared 393 following Chinese Pharmacopeia), as well as a 394 commercial extract sold as food supplement (94.79 395 µg/mL). The results obtained in this study are also 396 consistent with previously reported data, even if 397 Artemisinin concentration shows a pronounced 398 variability depending on the source, ranging from 60 399 μg/mL [22] to 200-500 μg/mL [23]. 400 To verify the uptake of artemisinin by the cells, 401 Artemisinin content was determined either in the 402 incubation media or in the OSCA-8 and OSCA-40 cell 403 lines after 24 hours of exposure to A. annua extract 404 or Artemisinin at the EC₅₀ doses (Table 1). Cells 405 actively took up Artemisinin, which reached a 406 concentration of 1.66 pg/cell in OSCA-40 cell line. In 407 both cell lines, the intracellular concentration of 408 Artemisinin is higher in the case of exposure to pure 409 Artemisinin than to the phytoextract, in agreement with the higher concentrations in the medium and higher EC₅₀ values.

The innovative analytical method gave the opportunity to accurately determine the concentration of Artemisinin taken up by cells and allowed an evidence-based discussion of the cytotoxic effects of the extracts.

Table 1. Artemisinin concentration determined in culture medium and in OSCA-8 and OSCA-40 cell lines after 24 hours of exposure to pure Artemisinin (A) and A. annua extract (E) at the EC $_{50}$ doses.

	Medium	Intacellular Artemisinin
	μg/mL	pg/cell
OSCA-8 (A)	4.05	2.54
OSCA-8 (E)	0.41	1.36
OSCA-40 (A)	3.76	2.42
OSCA-40 (E)	0.38	1.66

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

425 Artemisia annua hydroalcoholic extract is

426 cytotoxic for canine OSA cell lines

MTT assay was used to determine the effect of an A. annua hydroalcoholic extract containing 63.8 µg artemisinin/mL or primary compound Artemisinin on the growth of 2 different canine OS cell lines: OSCA-8 e OSCA-40. The *A. annua* hydroalcoholic extract showed a dose-dependent cytotoxic effect inhibiting the proliferation of the two canine OSA cell lines with EC₅₀ of 3.3 and 2.6 µM for OSCA-8 and OSCA-40 respectively, while Artemisinin showed an EC₅₀ of 2548 µM for OSCA-8 and of 878.3 µM for OSCA-40. (Figure 1). Accordingly, a similar toxic effect was previously reported for D-17 canine OSA cell line by Isani et al., (2019) [15] and a marked dosedependent toxic effect of an extract of A. annua, obtained by pressurized cyclic solid-liquid extraction, was reported by Culurciello et al. (2021) [16] on a different canine OS cell line (CRL2130). The extract presented significantly lower EC₅₀ values than Artemisinin (Fig. 1). The EC₅₀ values for Artemisinin determined in this study are one-order magnitude

lower than those reported for pure Artemisinin in two other canine tumour cell lines, DH82 and D-GBM, by Saeed et al. (2020) [24], suggesting a more potent cytotoxic effect of the phytoextract. Indeed, the extract contains many other cytotoxic compounds in addition to Artemisinin, including polyphenols, flavonoids, coumarins, and phytosterols. Important constituents are camphene, camphor, betacaryophyllene, pinene, 1,8-cineole, and scopoletin [25]. Volatile essential oils are also present at concentrations of 0.20-0.25%. All these secondary metabolites acting in a multi-specific manner against tumours can contribute to the toxic effect of the phytoextract [26]. The data reported in the present research add more evidence on the potency of A. annua extracts, which inhibit the growth of canine osteosarcoma cells, and might be considered anti-tumour candidate for further promising development.

466

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464




Figure 1_ *A. annua* hydroalcoholic extract and Artemisinin impair cell viability of the canine OSA cell lines OSCA-8 and OSCA-40. The cells were treated with increasing concentrations of *A. annua* hydroalcoholic extract, Artemisinin or vehicles for 24 h and the cell viability measured by MTT assay. Dose-response curves represent mean ± SD from three independent experiments with seven replicates each(n=3).

The cytotoxic effects of *A. annua* could be related to DNA damage, oxidative stress, and alteration of tumour-related signal transduction pathways [2, 24]. The effect of the extract on cell cycle was evaluated by flow cytometry and data were analysed with Flow Logic software. The cells grew as asynchronous populations represented by cells in all stages of the cell cycle. For OSCA40 cell line treated with *A. annua* extract and with Artemisinin at the EC₅₀ doses, the

gates were inserted manually because Dean-Jett-Fox Model failed to distinguish the different phases of the cell cycle. Considering the cells treated with the vehicles (EtOH or DMSO) as control, it can be observed that A. annua extract and Artemisinin treatments impair the cellular distribution in the different cell cycle phases. Particularly, in OSCA-8 cell line pure Artemisinin, but not A. annua extract, determined a significant decrease (P<0.05) of the cells in G0/G1 accompanied by a significant increase (P<0.001) of the cells in sub-G0/G1 phase. In OSCA-40, both treatments strongly influenced the cell distribution with significant decrease (p<0.05) of the cells in G0/G1 accompanied by a significant increase (p<0.001) of the cells in sub G0/G1 phase. (Fig. 2,3). These data add further evidence to the effects of Artemisinin on the cell cycle.

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503




Figure 2_ A. annua hydroalcoholic extract and Artemisinin impair cell cycle of the canine OSA cell lines. The cells were treated with A. annua extract and Artemisinin at the EC₅₀ doses

or vehicle (EtOH or DMSO) for 24 h and fluorescence of the PIstained cells was measured using MACSQuant® Analyzer10 and analysed by Flow Logic software (Inivai Technologies, Australia). 5 × 10⁵ cells were examined for each sample and experiment was repeated three times. Representative DNA content frequency histograms in OSCA-8 and OSCA-40. Sub G0/G1 blue/purple, G0/G1 red, S yellow, G2/M green.




Figure 3_ Grouped histograms graphs of cell cycle distribution in OSCA-8 and OSCA-40. The cell lines were treated with A. annua hydroalcoholic extract and Artemisinin at the EC₅₀ doses for 24 h or vehicles (EtOH or DMSO). Cell percentages were averaged over triplicate samples, and the data are expressed as the mean \pm SD. Paired Student's t-test, (*p<0.05, **p<0.01; ***p<0.001) was performed between controls and treated cells (n=3).

As a matter of fact, Artemisinin and its derivatives (dihydroartemisinin, artesunate, artemether, arteether) are known to affect the cell cycle of several types of tumour cells in different ways, depending on specific defects of the machinery regulating the cell

cycle of tumour cell lines [27]. In OSCA-8 the exposure to pure Artemisinin but, in OSCA-40, also the exposure to A. annua extract induced a significant decrease of the cells in G0/G1 accompanied by a significant increase of the cells in sub G0/G1 phase. The same profile was also reported for other canine and human OSA cell lines treated with dihydroartemisinin [14, 28]. A dose-dependent accumulation of MDA-MB-468 and SK-BR-3 breast cancer cells in the sub-G1 fraction following the exposure to artesunate, a semi-synthetic derivative Artemisinin, of has been reported also by Greenshields et al. (2019) [29]. Sub-G0/G1 peak is composed by dead cells (apoptosis, necrosis, oncosis) and by cells that had already lost their DNA by shedding apoptotic bodies, cellular fragments holding pieces of chromatin, broken nuclei, chromosomes, and cellular debris [30]. It could be hypothesised that Artemisinin in Α. annua hydroalcoholic extract extensively impairs DNA integrity in OSCA-40 cells and an efficient G1 checkpoint machinery hosted by this canine OSA cell line leads cells to die before replicating their damaged DNA. The DNA damage response (DDR) is a complex system, a network of biochemical

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

pathways that detects DNA damage and decides the cell fate. These pathways include the repair throughout different phases of proliferation, the delay of cell cycle, and the arrest of cell cycle to allow for more comprehensive DNA repair [31]. If the level of DNA damage exceeds the cells repairing ability, cell death is stimulated. DNA damage is caused by various internal and extrinsic factors including reactive oxygen species (ROS) and environmental mutagens [32]. In OSCA-8 cell line, where only pure Artemisinin is able to impair the cell cycle, the DNA damage induced by A. annua might be less extensive and unable to lead to a significant cell cycle impairment or the cellular repair machinery could be so efficient to allow a complete repair. This hypothesis is supported by the lower intracellular concentration of Artemisinin measured in OSCA-8 (Table 1).

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

Artemisia annua hydroalcoholic extract modifies intracellular iron content in canine OSA cell line

Tumours are characterized by high iron content, to satisfy their increased metabolic demand [5]. This is achieved through some crucial changes in iron metabolism, including the increased expression of

transferrin receptor-1 (TfR1) in many tumours [33], including cOSA [34]. The intracellular iron content influences the sensitivity of cells to ferroptosis. As a result, to study the iron involvement in the cytotoxicity of A. annua extract the need arose to measure the iron content in OSCA-8 and OSCA-40 cell lines with a sensitive and accurate method. This is a challenging task, due to the very small amount of the biological samples; consequently, specific elemental detector with low detection limit is needed. Complex analytical methods with different degree of accuracy and sensitivity are currently available to measure iron in cells, including FAAS, ICP-MS and TXRF [35]. The analytical FAAS method used in this research with a detection limit of 0.8 ng/mL was able to detect iron in all the samples analysed. Iron content in cells is reported in Figure 4. The variety of analytical methods and the related different units of measurement to express the intracellular iron content hamper the comparison with the data in the literature. Iron content in control untreated cells is like the value reported in canine D-17 OSA cells [15], if expressed as ng/1x106 cells. OSCA-40 cells treated with A. annua extract at the EC₅₀ dose had a significantly (p<0.05) higher iron content than those treated with

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

the vehicle, while no significant difference was detected for OSCA-8. An increase of intracellular iron content, though measured with a less accurate and specific colorimetric method, was also reported in Saos-2 and U2os human OSA cell lines treated with EF24, a synthetic analogue of curcumin [36]. In both cell lines, no significant effect of Artemisinin was detected in comparison with the vehicle (Figure 4).




Figure 4_ Intracellular iron content in OSCA-8 and OSCA-40. The vehicles (DMSO for Artemisinin and 65% EtOH for extract) were used as control. Data are expressed as pg Fe/cell and are reported as mean ± SD from three independent experiments (n=3), each performed in duplicate. Paired Student's t-test, (*p<0.05) was performed between control and treated cells.

Artemisia annua hydroalcoholic extract induces"ballooning" phenotype in canine OSA cell lines

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

Cells were exposed for 24 h to A. annua hydroalcoholic extract or to Artemisinin at the EC₅₀ doses and to 10 µM erastin to investigate the possible involvement of ferroptosis. Erastin, a well-known inducer of ferroptosis, inhibits cystine uptake by the cystine/glutamate antiporter (system decreasing the antioxidant defences of the cell, and ultimately leading to oxidative cell death [21]. Ferroptosis is dependent upon intracellular iron and is morphologically, biochemically, and genetically distinct from apoptosis, necrosis, and autophagy [21]. It is known that, following the treatment with a proferroptotic agent such as erastin, an initial cell shrinking is followed by condensation of cytoplasmic constituents and a "ballooning" phenotype, which involves the formation of a clear, rounded morphology consisting mainly of empty cytosol. The exact mechanisms underlying the phenotypic changes that occur during ferroptosis remain unclear [37]. In both cell lines treated with A. annua hydroalcoholic extract or with 10 µM erastin, and in OSCA-40 cells treated with pure Artemisinin, the microscopic examination revealed loss of attachment

to the culture plate and dead cells showed a clear "ballooning" phenotype suggesting that not only erastin but also *A. annua* could trigger ferroptosis in canine OS cell lines. (Fig. 5 b, c, f, g and h) In contrast, the cells treated with the vehicle (EtOH) had no evidence of cytotoxicity nor of such specific phenotype. (Fig. 5 a, e). On the other hand, the OSCA-8 cells treated with pure Artemisinin showed evidence of cytotoxicity, but not a clear "ballooning" phenotype. (Fig. 5d)




Figure 5_ *A. annua* hydroalcoholic extract induces "ballooning" phenotype in canine OSA cell lines OSCA-8 and OSCA-40. Representative images of OSCA-8 (a, b, c, d) and OSCA-40 (e, f, g, h) treated with *A. annua* hydroalcoholic extract at the EC₅₀ dose (b, f), erastin 10μM (c, g) or EtOH (a, e). Following the treatment with *A. annua* hydroalcoholic extract or erastin 10μM bothcell lines showed a "ballooning" phenotype which involves the formation of a clear, rounded morphology consisting mainly of empty cytosol (see in the boxes). In OSCA-

40, pure Artemisinin treatment induced a "ballooning" phenotype. Scale bar: 100 μm.

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

665

666

Artemisia annua hydroalcoholic extract induces

Lipid Peroxidation in canine OSA cell lines

In OSCA-8 and OSCA-40 canine OSA cell lines, the treatment with A. annua hydroalcoholic extract and with pure Artemisinin at the EC₅₀ doses for 24 h leads to extensive lipid peroxidation as indicated by a clear shift from red to green of the Lipid Peroxidation Sensor (Fig. 6). Lipid peroxidation is an oxidative degradation and ROS play a dual role, beneficial and/or deleterious. Indeed, a growing body of evidence shows that within cells ROS act as secondary messengers in intracellular signalling cascades, inducing and maintaining the oncogenic phenotype of cancer cells both in humans and dogs [38, 39]. However, ROS can also induce cellular senescence, apoptosis, ferroptosis and can therefore function as anti-tumourigenic species [38]. Artemisinin and its derivatives induce ROS overproduction, triggering peroxidation of membrane lipids and cell death in a wide range of cellular types, including plants, and mammalian cancer cells [8, 40]. The increase of ROS production in a dose-dependent manner was also reported by Hosoya et al. (2008) [14] in D-17 cOSA cell line treated with dihydroartemisinin. Since ferroptosis is associated with accumulation of lipid peroxides [21, 37] it could be further speculated that the cytotoxicity of *A. annua* involves ferroptotic cell death.




Figure 6_A. annua hydroalcoholic extract induces Lipid Peroxidation in canine OSA cell lines OSCA-8 and OSCA-40. Representative images of OSC-8 (a, b, c) and OSCA-40 (d,e,f) treated with *A. annua* hydroalcoholic extract at the EC₅₀ dose (b, e), with pure Artemisinin at the EC₅₀ dose (c,f) and controls (untreated cells, a, d). The cells were stained with 1X Lipid Peroxidation Sensor for 30 minutes in complete growth medium at 37°C and stained with Hoechst 33342 during the last 10 minutes of incubation. In b, c, e and f a clear shift from red to green was observed. Scale bar: 100 μm.

Involvement of ferroptosis

Three main traits define ferroptotic cell death, namely the increase of free iron, the accumulation of lipid peroxides, and a "ballooning" death phenotype that is morphologically distinct from autophagic, apoptotic, or necrotic cell death phenotypes [21]. In both cell lines, A. annua hydroalcoholic extract at the EC₅₀ doses triggered the appearance of a "ballooning" phenotype as well as extensive lipid peroxidation, while the iron content increased in OSCA-40, but not OSCA-8. Alteration of iron metabolism is recognized as central mediator of ferroptosis. Ferric ions bound to transferrin are imported into cells using the transferrin receptor 1 (TFR1) and then included in the endosome. In the endosome, ferric ions are reduced to ferrous ions and finally transported into the cytoplasm through the divalent metal transporter 1 (DMT1). In the cell cytoplasm a dynamic and controlled labile iron pool (LIP) is present and serves as a crossroad of intracellular iron metabolism [41]. In normal cells, this pool is maintained within a narrow range of concentration, while in cancer cells, a reduction of ferritin iron storage can increase the LIP and the risk of oxidative stress, which in turn is able to determine a massive lipid peroxidation. In different human tumour cell lines, including OSA,

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

exposed to dihydroartemisinin an increase of LIP has been reported, due to the increased lysosomemediated ferritin degradation [8]. However, despite an increasing number of studies, the role of iron in ferroptotic cell death is still to be completely understood, due to the complexity of iron metabolism and homeostasis. OSCA-40 cell line is more sensitive to the cytotoxic effect of the extract, has a lower EC₅₀ value for *A. annua* extract and or pure Artemisinin, a higher intracellular Artemisinin and iron content, and extensive lipid peroxidation associated with a "ballooning" phenotype appeared following the exposure to A. annua extract and to pure Artemisinin for 24 hours. This experimental evidence argues in favour of the activation of ferroptosis. Although the method for iron analysis used in this research allows the quantification of total intracellular iron, an imbalance of its metabolism can be hypothesised, leading to an increased ferritin degradation and finally to increased LIP. In OSCA-8 treated with A. annua extract, even in the presence of the "ballooning" phenotype and lipid peroxidation, no increase in total iron content and no impairment of cell cycle were observed. However, it cannot be excluded an increase of LIP without modifying the

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

intracellular content of iron as well as a different kinetics in DNA damage response mechanisms in the two cell lines.

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

The high chemoresistance is a negative trait of most OS [42] and ferroptosis is considered as an interesting therapeutic strategy to overcome multidrug resistance. Recently, it has been reported that ferroptosis makes OSA cells more susceptible to doxorubicin. collaboratively strengthening apoptosis-based doxorubicin chemotherapy [43]. Therefore A. annua may be especially effective in treating drug resistant osteosarcomas. Considering the similarities between many human and canine tumours, advances in deepening knowledge and improving therapeutic protocols may be relevant for both species, in a model of mutual translational medicine. The relevance of *A. annua* as anticancer compound is enhanced by the fact that it is cheap, as compared to other pharmacological interventions available on the market. This could be an advantage for low-income countries [44] or contexts such as for the dog owners' reluctance to choose chemotherapy treatments.

784 **4. Conclusions**

785 The idroalcoholic extract of A. annua showed 786 cytotoxicity on two canine OSA cell lines with 787 increase of total iron, accumulation of lipid peroxides 788 and a "ballooning" death phenotype, suggesting the 789 activation of ferroptosis. However, it should be 790 emphasized that any conclusions from this study 791 must necessarily be confirmed on more cell lines. 792 793 **Author Contributions:** 794 Conceptualization: GI, GA, MF 795 Methodology: RS, CB, DLM, AZ, MF, GA, LM, MP 796 Validation, formal analysis: RS, CB, DLM, AZ, MF, GA, 797 GI, LM, MP 798 Data curation: RS, CB, DLM, AZ, MF, GA, LM 799 Writing—original draft preparation: GI, RS, LM 800 Writing—review and editing: GI, GA, LM, MP 801 Project administration and funding acquisition: GI. 802 All authors have read and agreed to the published version 803 of the manuscript. 804 Funding: This research was supported by a grant from 805 "Fondazione Carisbo" (Bologna) (2019.0535, project title:

- 806 Attività antitumorale di estratti di Artemisia in colture
- 807 cellulari di osteosarcoma di cane: un progetto
- 808 multidisciplinare di medicina traslazionale).
- 809 **Conflicts of Interest**: The authors declare no conflict of
- 810 interest.

811

References

- 1. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from
- 813 Chinese medicine. Nat Med. 2011;17:1217–20.
- 2. Efferth T. From ancient herb to modern drug: Artemisia annua and
- artemisinin for cancer therapy. Semin Cancer Biol. 2017;46:65–83.
- 816 3. Ho WE, Peh HY, Chan TK, Wong WSF. Artemisinins:
- 817 pharmacological actions beyond anti-malarial. Pharmacol Ther.
- 818 2014;142:126–39.
- 4. Zhu S, Yu Q, Huo C, Li Y, He L, Ran B, et al. Ferroptosis: A Novel
- 820 Mechanism of Artemisinin and its Derivatives in Cancer Therapy.
- 821 Curr Med Chem. 2021;28:329–45.
- 5. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev
- 823 Cancer. 2013;13:342–55.
- 6. Krishna S, Uhlemann A-C, Haynes RK. Artemisinins: mechanisms
- of action and potential for resistance. Drug Resist Updat. 2004;7:233–
- 826 44.
- 7. Farcas N, Arzi B, Verstraete FJM. Oral and maxillofacial
- 828 osteosarcoma in dogs: a review: Canine oral osteosarcoma. Vet Comp

- 829 Oncol. 2014;12:169-80.
- 830 8. Chen G-Q, Benthani FA, Wu J, Liang D, Bian Z-X, Jiang X.
- 831 Artemisinin compounds sensitize cancer cells to ferroptosis by
- regulating iron homeostasis. Cell Death Differ. 2020;27:242–54.
- 9. Gola C, Giannuzzi D, Rinaldi A, Iussich S, Modesto P, Morello E,
- 834 et al. Genomic and Transcriptomic Characterization of Canine
- 835 Osteosarcoma Cell Lines: A Valuable Resource in Translational
- 836 Medicine. Front Vet Sci. 2021;8:666838.
- 837 10. Massimini M, Romanucci M, De Maria R, Della Salda L. An
- Update on Molecular Pathways Regulating Vasculogenic Mimicry in
- Human Osteosarcoma and Their Role in Canine Oncology. Front Vet
- 840 Sci. 2021;8:722432.
- 841 11. Sánchez-Céspedes R, Accornero P, Miretti S, Martignani E,
- Gattino F, Maniscalco L, et al. In vitro and in vivo effects of toceranib
- phosphate on canine osteosarcoma cell lines and xenograft orthotopic
- models. Veterinary and Comparative Oncology. 2020;18:117–27.
- 845 12. Morello E, Martano M, Buracco P. Biology, diagnosis and
- 846 treatment of canine appendicular osteosarcoma: Similarities and
- differences with human osteosarcoma. The Veterinary Journal.
- 848 2011;189:268–77.
- 849 13. Meuten DJ, editor. Tumors in Domestic Animals. Hoboken, NJ,
- 850 USA: John Wiley & Sons, Inc.; 2016.
- 14. Hosoya K, Murahari S, Laio A, London CA, Couto CG, Kisseberth
- WC. Biological activity of dihydroartemisinin in canine osteosarcoma
- 853 cell lines. Am J Vet Res. 2008;69:519–26.

- 854 15. Isani G, Bertocchi M, Andreani G, Farruggia G, Cappadone C,
- 855 Salaroli R, et al. Cytotoxic Effects of Artemisia annua L. and Pure
- Artemisinin on the D-17 Canine Osteosarcoma Cell Line. Oxid Med
- 857 Cell Longev. 2019;2019:1615758.
- 858 16. Culurciello R, Bosso A, Di Fabio G, Zarrelli A, Arciello A, Carella
- F, et al. Cytotoxicity of an Innovative Pressurised Cyclic Solid-Liquid
- 860 (PCSL) Extract from Artemisia annua. Toxins (Basel). 2021;13:886.
- 17. Protti M, Mandrioli R, Mandrone M, Cappadone C, Farruggia G,
- 862 Chiocchio I, et al. Analysis of Artemisia annua extracts and related
- products by high performance liquid chromatography-tandem mass
- spectrometry coupled to sample treatment miniaturisation. J Pharm
- 865 Biomed Anal. 2019;174:81–8.
- 866 18. Levi M, Salaroli R, Parenti F, De Maria R, Zannoni A, Bernardini
- 867 C, et al. Doxorubicin treatment modulates chemoresistance and affects
- the cell cycle in two canine mammary tumour cell lines. BMC Vet
- 869 Res. 2021;17:30.
- 870 19. Fox MH. A model for the computer analysis of synchronous DNA
- distributions obtained by flow cytometry. Cytometry. 1980;1:71–7.
- 872 20. Tüzen M. Determination of heavy metals in soil, mushroom and
- 873 plant samples by atomic absorption spectrometry. Microchemical
- 874 Journal. 2003;74:289–97.
- 21. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM,
- 876 Gleason CE, et al. Ferroptosis: an iron-dependent form of
- 877 nonapoptotic cell death. Cell. 2012;149:1060–72.
- 878 22. Bai H, Wang C, Chen J, Peng J, Cao Q. A novel sensitive
- 879 electrochemical sensor based on in-situ polymerized molecularly

- imprinted membranes at graphene modified electrode for artemisinin
- determination. Biosens Bioelectron. 2015;64:352–8.
- 882 23. Soktoeva TE, Ryzhova GL, Dychko KA, Khasanov VV,
- 283 Zhigzhitzhapova SV, Radnaeva LD. Artemisinin content in Artemisia
- annua L. extracts obtained by different methods. Russ J Bioorg Chem.
- 885 2013;39:761-4.
- 886 24. Saeed MEM, Breuer E, Hegazy M-EF, Efferth T. Retrospective
- study of small pet tumors treated with Artemisia annua and iron. Int J
- 888 Oncol. 2020;56:123–38.
- 25. Ferreira JFS, Luthria DL, Sasaki T, Heyerick A. Flavonoids from
- 890 Artemisia annua L. as antioxidants and their potential synergism with
- artemisinin against malaria and cancer. Molecules. 2010;15:3135–70.
- 892 26. Efferth T, Herrmann F, Tahrani A, Wink M. Cytotoxic activity of
- 893 secondary metabolites derived from Artemisia annua L. towards
- 894 cancer cells in comparison to its designated active constituent
- artemisinin. Phytomedicine. 2011;18:959–69.
- 896 27. Fenger JM, London CA, Kisseberth WC. Canine osteosarcoma: a
- 897 naturally occurring disease to inform pediatric oncology. ILAR J.
- 898 2014;55:69–85.
- 899 28. Ji Y, Zhang Y-C, Pei L-B, Shi L-L, Yan J-L, Ma X-H. Anti-tumor
- 900 effects of dihydroartemisinin on human osteosarcoma. Mol Cell
- 901 Biochem. 2011;351:99–108.
- 902 29. Greenshields AL, Fernando W, Hoskin DW. The anti-malarial
- 903 drug artesunate causes cell cycle arrest and apoptosis of triple-negative
- 904 MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp
- 905 Mol Pathol. 2019;107:10–22.

- 906 30. Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP,
- 907 Rutland CS. Comparative review of human and canine osteosarcoma:
- 908 morphology, epidemiology, prognosis, treatment and genetics. Acta
- 909 Vet Scand. 2017;59:71.
- 910 31. Kuczler MD, Olseen AM, Pienta KJ, Amend SR. ROS-induced
- 911 cell cycle arrest as a mechanism of resistance in polyaneuploid cancer
- 912 cells (PACCs). Prog Biophys Mol Biol. 2021;165:3–7.
- 913 32. Matsui A, Hashiguchi K, Suzuki M, Zhang-Akiyama Q-M.
- 914 Oxidation resistance 1 functions in the maintenance of cellular
- 915 survival and genome stability in response to oxidative stress-
- 916 independent DNA damage. Genes Environ. 2020;42:29.
- 917 33. Brown RAM, Richardson KL, Kabir TD, Trinder D, Ganss R,
- 918 Leedman PJ. Altered Iron Metabolism and Impact in Cancer Biology,
- 919 Metastasis, and Immunology. Front Oncol. 2020;10:476.
- 920 34. De Vico G, Martano M, Maiolino P, Carella F, Leonardi L.
- 921 Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas.
- 922 Vet Med Sci. 2020;6:272-6.
- 923 35. Cerchiaro G, Manieri TM, Bertuchi FR. Analytical methods for
- opper, zinc and iron quantification in mammalian cells. Metallomics.
- 925 2013;5:1336–45.
- 926 36. Lin H, Chen X, Zhang C, Yang T, Deng Z, Song Y, et al. EF24
- 927 induces ferroptosis in osteosarcoma cells through HMOX1.
- 928 Biomedicine & Pharmacotherapy. 2021;136:111202.
- 929 37. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical
- 930 role in mitigating lipid peroxidation and ferroptosis. Redox Biol.
- 931 2019;23:101107.

- 932 38. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J.
- 933 Free radicals and antioxidants in normal physiological functions and
- human disease. Int J Biochem Cell Biol. 2007;39:44–84.
- 935 39. Macotpet A, Suksawat F, Sukon P, Pimpakdee K,
- Pattarapanwichien E, Tangrassameeprasert R, et al. Oxidative stress in
- 937 cancer-bearing dogs assessed by measuring serum malondialdehyde.
- 938 BMC Vet Res. 2013;9:101.
- 939 40. Yan Z-Q, Wang D-D, Ding L, Cui H-Y, Jin H, Yang X-Y, et al.
- Mechanism of artemisinin phytotoxicity action: induction of reactive
- 941 oxygen species and cell death in lettuce seedlings. Plant Physiol
- 942 Biochem. 2015;88:53-9.
- 943 41. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization,
- measurement, and participation in cellular processes(1). Free Radic
- 945 Biol Med. 2002;33:1037–46.
- 946 42. Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra
- 947 M. Drug Resistance in Osteosarcoma: Emerging Biomarkers,
- 948 Therapeutic Targets and Treatment Strategies. Cancers (Basel).
- 949 2021;13:2878.
- 950 43. Fu J, Li T, Yang Y, Jiang L, Wang W, Fu L, et al. Activatable
- 951 nanomedicine for overcoming hypoxia-induced resistance to
- chemotherapy and inhibiting tumor growth by inducing collaborative
- 953 apoptosis and ferroptosis in solid tumors. Biomaterials.
- 954 2021;268:120537.
- 955 44. Waseem Y, Hasan CA, Ahmed F. Artemisinin: A Promising
- 956 Adjunct for Cancer Therapy. Cureus. 2018;10:e3628.